Company intelligence / Profile preview

Cytovale

San Francisco, California, United Statescytovale.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cytovale’s IntelliSep test, powered by the proprietary Cytovale System, has demonstrated a high negative predictive value (~98%) for sepsis in emergency department patients. Clinical studies show it enables rapid (<10 minutes) and accurate risk stratification for sepsis, reducing mortality by over 30% and delivering significant cost savings per patient tested. The system provides actionable results to guide early intervention in hospitals.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic testMicrofluidics-based technologyMachine learning-enabled diagnostics
Industry: Pathology

Beyond the preview

Go deeper on Cytovale.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytovale.

Explore the full profile